The US patent for abrocitinib, US 9,035,074 B2, was granted on May 19, 2015. This patent, titled "ABROCITINIB AND PREPARATIONS THEREOF," is assigned to Pfizer Inc. [1].
What does US Patent 9,035,074 B2 cover for abrocitinib?
US Patent 9,035,074 B2 specifically claims abrocitinib itself, along with various pharmaceutical compositions and methods of use related to the compound [1]. Abrocitinib is a JAK1 inhibitor developed for the treatment of atopic dermatitis [2].
When does the patent for abrocitinib expire?
While the original grant date for US 9,035,074 B2 was May 19, 2015, the patent term is subject to adjustments and potential extensions. For a more precise determination of the patent expiry date, including any regulatory extensions such as those granted under the Hatch-Waxman Act, it is advisable to consult patent databases like DrugPatentWatch.com [1].
What other patents protect abrocitinib?
In addition to US 9,035,074 B2, abrocitinib is protected by other patents covering its synthesis, formulations, and methods of treatment. These patents contribute to the overall intellectual property protection of the drug. Detailed patent information, including related filings and their status, can be found through specialized patent search tools [1].
Who is developing and marketing abrocitinib?
Abrocitinib is developed and marketed by Pfizer Inc. under the brand name Cibinqo [3][2].
What is abrocitinib used to treat?
Abrocitinib (Cibinqo) is indicated for the treatment of moderate-to-severe atopic dermatitis in adult and adolescent patients 12 years and older whose disease is not adequately controlled by topical therapies or when those therapies are otherwise inappropriate [2].
How does abrocitinib work?
Abrocitinib is an oral Janus kinase 1 (JAK1) inhibitor. By inhibiting JAK1, it modulates the signaling pathways involved in inflammation and immune responses associated with atopic dermatitis [2].